Because it takes so long for men with even advanced prostate cancer to progress through to death from any cause, there has been extensive effort over the years to define “surrogate” endpoints for prostate cancer-specific and overall survival in prostate cancer clinical trials.
Filed under: Drugs in development | Tagged: enpoint, overall, PSA progression, surrogate, survival | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
